Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose intravenous immunoglobulin for antibody-mediated rejection after kidney transplantation
jRCT1041240202Recruiting
- Start
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of immune globulin in humoral rejection, sponsored by None. Primary endpoint: Change in Banff histologic scores. Started Mar 2025; status: recruiting.
02
Drugs
immune globulin
03
Conditions
humoral rejection
Beyond the preview
Go deeper on jRCT1041240202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1041240202.